Anonymous Client G — Gene therapy company preparing for first commercial launch ($2.1M target price)
The gene therapy landscape was evolving rapidly, with 5 one-time therapies launched in the past 3 years at prices ranging from $850K to $2.1M. Payer willingness-to-pay varied dramatically — some payers had established gene therapy coverage policies, while others required extensive evidence and outcomes-based agreements. The client's cost-effectiveness analysis showed a $2.5M value-based price, but payers were increasingly questioning cost-effectiveness models for one-time therapies with limited long-term durability data.
A gene therapy company preparing for their first commercial launch faced unprecedented pricing challenges. Their therapy was a one-time treatment for a rare pediatric disease with an addressable population of 3,000 patients in the US. The company wanted to price at $2.1M per patient based on cost-effectiveness analysis, but had no experience with payer negotiations, no outcomes-based agreement templates, and no understanding of payer willingness-to-pay for one-time therapies. Three recent gene therapy launches had struggled with payer access, and 2 had been forced to accept significant price reductions.
We developed a comprehensive pricing and market access strategy that balanced value-based pricing with payer realism. Our approach included: (1) value-based pricing framework supported by budget impact models and HEOR evidence, (2) payer landscaping across 20+ payer organizations with willingness-to-pay analysis, (3) outcomes-based agreement design with risk-sharing models, (4) innovative payment models including annuity-based payments and reinsurance mechanisms, and (5) stakeholder engagement roadmap with patient advocacy alignment.
Value-based pricing analysis: Built a cost-effectiveness model incorporating lifetime clinical benefits, QALY gains, healthcare cost offsets, and caregiver burden reduction
Payer landscaping: Conducted structured interviews with 20+ payer organizations (commercial, Medicare, Medicaid) to assess willingness-to-pay and coverage requirements
Budget impact modeling: Developed payer-specific budget impact models showing 1-year, 3-year, and 5-year financial implications at various price points
Outcomes-based agreement design: Created 3 outcomes-based agreement templates with risk-sharing mechanisms, milestone payments, and durability guarantees
Innovative payment model analysis: Evaluated annuity-based payment structures, reinsurance models, and value-based annuity contracts
Competitive pricing benchmarking: Analyzed pricing, access, and outcomes agreements for 5 launched gene therapies
Patient advocacy alignment: Engaged 8 patient advocacy organizations to build support for access and pricing strategy
We recommended a launch price of $2.1M per patient with a multi-layered access strategy: (1) outcomes-based agreements for payers requiring risk-sharing (30% of patients), (2) annuity-based payments over 5 years for budget-constrained payers (25% of patients), (3) reinsurance-backed coverage for small payers (15% of patients), and (4) standard fee-for-service for large commercial payers (30% of patients). We projected 85% payer coverage within 12 months of launch.
Phase 1 (Weeks 1-5): Value-based pricing analysis and HEOR evidence generation plan
Phase 2 (Weeks 3-8): Payer landscaping with 20+ structured interviews and budget impact modeling
Phase 3 (Weeks 7-12): Outcomes-based agreement design and innovative payment model analysis
Phase 4 (Weeks 11-15): Payer engagement playbook and stakeholder engagement roadmap
Phase 5 (Weeks 14-18): Final pricing strategy, access agreements, and launch readiness support
| Metric | Before | After | Impact |
|---|---|---|---|
| Launch Price | TBD | $2.1M per patient | Achieved target price through multi-layered access strategy |
| Payer Coverage (12 months) | Unknown | 85% projected | Multi-layered access approach enabled broad coverage |
| Outcomes-Based Agreements | 0 | 15 agreements | Risk-sharing enabled payer comfort with high price point |
| Net Revenue per Patient | Uncertain | $2.1M (target achieved) | Value-based pricing with outcomes agreements balanced access and revenue |
| Patient Advocacy Support | No relationships | 8 organizations engaged | Strong advocacy support strengthened payer negotiations |
“Pricing a one-time gene therapy is completely different from pricing a chronic therapy. Medifirm understood the nuances — the outcomes-based agreements, the annuity models, the payer psychology. We achieved our $2.1M target price while securing 85% projected coverage. Without their strategy, we would have been forced to discount to $1.5M.”
Chief Commercial Officer
Anonymous Client G
Forecast
Value-based pricing with outcomes-based agreements projected to achieve $2.1M net revenue per patient, balancing access sustainability with innovation reward.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.